IP Library Granted Patent US 10,806,769
Granted Patent B2
US 10,806,769 · App. 15/476,018 · Granted Oct 20, 2020

Antimicrobial peptide stimulating cleansing composition

Inventors: Kegui Tian (Hudson, OH); Jessica Rae Tittl (Chagrin Falls, OH); Venkatesan V. Padyachi (Kendall Park, NJ)
Assignee: GOJO Industries, Inc.
A61K38/08A61K8/64A61K8/97A61K9/0014A61K36/55A61K38/07A61K47/20A61L2/0088A61Q17/005A61K2800/596A61L2202/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,806,769
App. No.
15/476,018
Granted
Oct 20, 2020
Kind
B2
Abstract

A topical cleansing composition for stimulating the production of antimicrobial peptides on the skin is disclosed. The topical cleansing composition includes an active ingredient comprising one or more of a natural extract and a polypeptide; one or more surfactants; and water. The topical cleansing composition increases the concentration of antimicrobial peptides on skin, as compared to an otherwise identical topical composition without the active ingredient.

Claims (15)

1. A topical cleansing composition for stimulating the production of antimicrobial peptides on the skin, said topical cleansing composition comprising:

about 0.02 wt. % to about 5 wt.% of an active ingredient, the active ingredient comprising at least one of linseed extract, flaxseed extract, hemp seed extract, and grapefruit seed extract;

about 3 wt. % to about 13 wt. % of one or more primary surfactants comprising sodium laureth sulfate;

one or more foaming agents in an amount up to about 35 wt.%; and

water, wherein the topical cleansing composition increases the concentration of antimicrobial peptides on skin, as compared to an otherwise identical topical composition without the active ingredient.

2. The topical cleansing composition of claim 1 , wherein the active ingredient is a polypeptide.

3. The topical cleansing composition of claim 1 , wherein the topical cleansing composition comprises about 0.05 to about 5.0 wt. % active ingredient, based on the weight of the total composition.

4. The topical cleansing composition of claim 1 , wherein the topical cleansing composition comprises about 0.1 to about 1.0 wt. % active ingredient, based on the weight of the total composition.

5. The topical cleansing composition of claim 1 , wherein the topical composition comprises one or more humectants, selected from the group consisting of propylene glycol, hexylene glycol, 1,4-dihydroxyhexane, 1,2,6-hexanetriol, sorbitol, butylene glycol, caprylyl glycol, propanediols, dipropylene glycol, triethylene glycol, glycerin, polyethylene glycols, ethoxydiglycol, polyethylene sorbitol, and combinations thereof.

6. The topical cleansing composition of claim 5 , wherein the humectant is present in an amount up to about 20.0 wt. %, based on the weight of the total composition.

7. The topical cleansing composition of claim 1 , wherein the topical composition increases the concentration of HBD-1 by at least about 10%, relative to an otherwise identical topical composition without said active ingredient.

8. The topical cleansing composition of claim 1 , wherein the topical composition increases the concentration of HBD-2 by at least about 5%, relative to an otherwise identical topical composition without said active ingredient.

9. The topical cleansing composition of claim 1 , wherein the topical composition increases the concentration of HBD-3 by at least about 5%, relative to an otherwise identical topical composition without said active ingredient.

10. The topical cleansing composition of claim 1 , wherein the topical composition increases the concentration of LL-37 by at least about 5%, relative to an otherwise identical topical composition without said active ingredient.

11. The topical cleansing composition of claim 1 , wherein the topical composition decreases the concentration of IL-8 by at least about 5%, relative to an otherwise identical topical composition without said active ingredient.

Assignments (7)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL, RECORDED ON OCTOBER 27, 2023 AT REEL 065382 FRAME 0587 Recorded Apr 22, 2026
From: SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT
To: GOJO INDUSTRIES, INC.
Reel/Frame 075435/0852 →
RELEASE OF SECURITY INTEREST Recorded Apr 7, 2026
From: PNC BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: GOJO INDUSTRIES, INC.
Reel/Frame 074903/0480 →
SECURITY INTEREST Recorded Oct 27, 2023
From: GOJO INDUSTRIES, INC.
To: SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT
Reel/Frame 065382/0587 →
SECURITY INTEREST Recorded Oct 26, 2023
From: GOJO INDUSTRIES, INC.
To: PNC BANK, NATIONAL ASSOCIATION
Reel/Frame 065369/0253 →
SECURITY INTEREST Recorded Dec 9, 2019
From: GOJO INDUSTRIES, INC.
To: PNC BANK, NATIONAL ASSOCIATION
Reel/Frame 051228/0667 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2019
From: PADYACHI, VEKATESAN V.
To: GOJO INDUSTRIES, INC.
Reel/Frame 048092/0008 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2017
From: TIAN, KEGUI; TITTL, JESSICA RAE
To: GOJO INDUSTRIES, INC.
Reel/Frame 043578/0814 →
Continuity (2)
Provisional Application 62316123 · Mar 31, 2016
Related Publication 20170281717A1 · Oct 5, 2017
Cited By (2)
US 12,539,324 US 12,594,229